A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors | MicrobiomeTrials← Back to trialsNCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-03-21Est. Completion: 2029-06-18
Enrollment target: 450 participants Locations- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
- City of Hope - Duarte Cancer Center, Duarte, California, United States
- UCLA Health Bowyer Oncology Center, Los Angeles, California, United States
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco, California, United States
- Stanford University Medical Center - Neurology, Stanford, California, United States
- UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, Colorado, United States
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's, Denver, Colorado, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona, Orlando, Florida, United States
- Massachusetts General Hospital - Neurology, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute - Oncology Department, Boston, Massachusetts, United States
- START | Midwest, Grand Rapids, Michigan, United States
- Icahn School of Medicine at Mount Sinai - Oncology, New York, New York, United States
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York, New York, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- NEXT Dallas - Oncology Department, Irving, Texas, United States
- START | San Antonio, San Antonio, Texas, United States
- Froedtert Hospital - Clinical Cancer Center, Milwaukee, Wisconsin, United States
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
- Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre, Concord, New South Wales, Australia
- Northern Hospital, Epping, New South Wales, Australia
- Calvary Mater Hospital Newcastle - Oncology, Waratah, New South Wales, Australia
- Antwerp University Hospital | Oncology Department, Antwerp, Antwerp, Belgium
- Ghent University Hospital | Drug Research Unit Department, Ghent, East Flanders, Belgium
- UZ Leuven Gasthuisberg - Pneumology Department, Leuven, Flemish Brabant, Belgium
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology, Liège, Belgium
- Beijing Cancer Hospital - Oncology Department, Beijing, Beijing Municipality, China
- Beijing chest hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan, Hubei, China
- Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department, Hangzhou, Zhejiang, China
- Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Olomouc Region, Czechia
- Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP), Brno, South Moravian, Czechia
- Rigshospitalet Copenhagen University Hospital | Oncology Department, Copenhagen, Capital Region / Region Hovedstaden, Denmark
- Odense University Hospital | Svendborg Sygehus - Oncology Department, Odense, Region of Southern Denmark / Region Syddanmark, Denmark
- Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati, Aviano, Friuli Venezia Giulia, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I, Rome, Lazio, Italy
- I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione, Rome, Lazio, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1, Milan, Lombardy, Italy
- Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia, Rozzano, Lombardy, Italy
- Nagoya University Hospital, Nagoya, Aichi-ken, Japan
- National Cancer Center Hospital East, Kashiwa, Chiba, Japan
- Kindai University Hospital, Sakai, Osaka, Japan
- Shizuoka Cancer Center, Sunto, Shizuoka, Japan
- National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
- The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
- Nederlands Kanker Instituut, Amsterdam, North Holland, Netherlands
- Erasmus Medisch Centrum, Rotterdam, South Holland, Netherlands
- Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center, Groningen, Netherlands
- National University Hospital Medical Centre, Singapore, Singapore
- National Cancer Center Singapore - Oncology Department, Singapore, Singapore
- Icon Cancer Centre, Singapore, Singapore
- Clinica Universidad De Navarra | Pamplona | Oncologia, Pamplona, Chartered Community Of Navarre, Spain
- Hospital San Pedro | Oncologia, Logroño, La Rioja, Spain
- NEXT - Hospital Universitario Quironsalud Madrid | Oncologia, Pozuelo de Alarcón, Madrid, Spain
- Hospital Hm Nou Delfos | Oncologia, Barcelona, Spain
- Hospital Universitari Vall D Hebron | Oncologia, Barcelona, Spain
- Hospital Universitario Fundacion Jimenez Diaz | Oncologia, Madrid, Spain
- Hospital Universitario Virgen De La Victoria | Oncologia, Málaga, Spain
- Hospital Clinico Universitario De Valencia | Oncologia, Valencia, Spain
- Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC, Stockholm, Stockholm County, Sweden
- Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH, Gothenburg, Västra Götaland County, Sweden
- The Christie Hospital | Experimental Cancer Medicine Team, Manchester, Greater Manchester, United Kingdom
- The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit, Sutton, Surrey, United Kingdom
Other microbiome trials you might be interested in
Advanced Solid Tumor
The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability when…
Boston, United StatesEst. completion May 2028
Advanced Solid Tumors
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in parti…
Boston, United StatesEst. completion Jan 2029